Cold Atmospheric Plasma Inhibits HIV-1 Replication in Macrophages by Targeting Both the Virus and the Cells.

Cold atmospheric plasma (CAP) is a specific type of partially ionized gas that is less than 104°F at the point of application. It was recently shown that CAP can be used for decontamination and sterilization, as well as anti-cancer treatment. Here, we investigated the effects of CAP on HIV-1 replica...

Full description

Bibliographic Details
Main Authors: Olga Volotskova, Larisa Dubrovsky, Michael Keidar, Michael Bukrinsky
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5081187?pdf=render
id doaj-8aebc6ceb0f04b5b855be35349ef1fae
record_format Article
spelling doaj-8aebc6ceb0f04b5b855be35349ef1fae2020-11-25T01:42:33ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-011110e016532210.1371/journal.pone.0165322Cold Atmospheric Plasma Inhibits HIV-1 Replication in Macrophages by Targeting Both the Virus and the Cells.Olga VolotskovaLarisa DubrovskyMichael KeidarMichael BukrinskyCold atmospheric plasma (CAP) is a specific type of partially ionized gas that is less than 104°F at the point of application. It was recently shown that CAP can be used for decontamination and sterilization, as well as anti-cancer treatment. Here, we investigated the effects of CAP on HIV-1 replication in monocyte-derived macrophages (MDM). We demonstrate that pre-treatment of MDM with CAP reduced levels of CD4 and CCR5, inhibiting virus-cell fusion, viral reverse transcription and integration. In addition, CAP pre-treatment affected cellular factors required for post-entry events, as replication of VSV-G-pseudotyped HIV-1, which by-passes HIV receptor-mediated fusion at the plasma membrane during entry, was also inhibited. Interestingly, virus particles produced by CAP-treated cells had reduced infectivity, suggesting that the inhibitory effect of CAP extended to the second cycle of infection. These results demonstrate that anti-HIV activity of CAP involves the effects on target cells and the virus, and suggest that CAP may be considered for potential application as an anti-HIV treatment.http://europepmc.org/articles/PMC5081187?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Olga Volotskova
Larisa Dubrovsky
Michael Keidar
Michael Bukrinsky
spellingShingle Olga Volotskova
Larisa Dubrovsky
Michael Keidar
Michael Bukrinsky
Cold Atmospheric Plasma Inhibits HIV-1 Replication in Macrophages by Targeting Both the Virus and the Cells.
PLoS ONE
author_facet Olga Volotskova
Larisa Dubrovsky
Michael Keidar
Michael Bukrinsky
author_sort Olga Volotskova
title Cold Atmospheric Plasma Inhibits HIV-1 Replication in Macrophages by Targeting Both the Virus and the Cells.
title_short Cold Atmospheric Plasma Inhibits HIV-1 Replication in Macrophages by Targeting Both the Virus and the Cells.
title_full Cold Atmospheric Plasma Inhibits HIV-1 Replication in Macrophages by Targeting Both the Virus and the Cells.
title_fullStr Cold Atmospheric Plasma Inhibits HIV-1 Replication in Macrophages by Targeting Both the Virus and the Cells.
title_full_unstemmed Cold Atmospheric Plasma Inhibits HIV-1 Replication in Macrophages by Targeting Both the Virus and the Cells.
title_sort cold atmospheric plasma inhibits hiv-1 replication in macrophages by targeting both the virus and the cells.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2016-01-01
description Cold atmospheric plasma (CAP) is a specific type of partially ionized gas that is less than 104°F at the point of application. It was recently shown that CAP can be used for decontamination and sterilization, as well as anti-cancer treatment. Here, we investigated the effects of CAP on HIV-1 replication in monocyte-derived macrophages (MDM). We demonstrate that pre-treatment of MDM with CAP reduced levels of CD4 and CCR5, inhibiting virus-cell fusion, viral reverse transcription and integration. In addition, CAP pre-treatment affected cellular factors required for post-entry events, as replication of VSV-G-pseudotyped HIV-1, which by-passes HIV receptor-mediated fusion at the plasma membrane during entry, was also inhibited. Interestingly, virus particles produced by CAP-treated cells had reduced infectivity, suggesting that the inhibitory effect of CAP extended to the second cycle of infection. These results demonstrate that anti-HIV activity of CAP involves the effects on target cells and the virus, and suggest that CAP may be considered for potential application as an anti-HIV treatment.
url http://europepmc.org/articles/PMC5081187?pdf=render
work_keys_str_mv AT olgavolotskova coldatmosphericplasmainhibitshiv1replicationinmacrophagesbytargetingboththevirusandthecells
AT larisadubrovsky coldatmosphericplasmainhibitshiv1replicationinmacrophagesbytargetingboththevirusandthecells
AT michaelkeidar coldatmosphericplasmainhibitshiv1replicationinmacrophagesbytargetingboththevirusandthecells
AT michaelbukrinsky coldatmosphericplasmainhibitshiv1replicationinmacrophagesbytargetingboththevirusandthecells
_version_ 1725035532671516672